A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

NCT07557004 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+ / HER2- Advanced Breast Cancer

Interventions

DRUG: SH3765+Fulvestrant

Sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd.